Mail

UK markets closed

FTSE 100
8,139.83
+60.97(+0.75%)
FTSE 250
19,824.16
+222.18(+1.13%)
AIM
755.28
+2.16(+0.29%)
GBP/EUR
1.1675
+0.0018(+0.16%)
GBP/USD
1.2490
-0.0021(-0.17%)
Bitcoin GBP
50,921.57
-897.80(-1.73%)

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Bio-Rad Laboratories, Inc. (BIO)

NYSE - Nasdaq Real-time price. Currency in USD

Add to watchlist

278.45

+2.85

(+1.03%)

As of 01:07PM EDT. Market open.

Currency in USD

Valuation measures⁴

Market cap (intra-day)	7.88B
Enterprise value	7.68B
Trailing P/E	N/A
Forward P/E	24.75
PEG ratio (5-yr expected)	1.07
Price/sales (ttm)	3.01
Price/book (mrq)	0.90
Enterprise value/revenue	2.88
Enterprise value/EBITDA	-11.73

Trading information

Stock price history

Beta (5Y monthly)	0.88
52-week change ³	-38.86%
S&P500 52-week change ³	21.08%
52-week high ³	473.50
52-week low ³	261.59
50-day moving average ³	325.61
200-day moving average ³	338.13

Share statistics

Avg vol (3-month) ³	205.63k
Avg vol (10-day) ³	234.7k
Shares outstanding ⁵	23.42M
Implied shares outstanding ⁶	28.6M
Float ⁸	19.96M
% held by insiders ¹	15.24%
% held by institutions ¹	83.48%
Shares short (15 Apr 2024) ⁴	688.47k
Short ratio (15 Apr 2024) ⁴	3.77
Short % of float (15 Apr 2024) ⁴	3.86%
Short % of shares outstanding (15 Apr 2024) ⁴	2.41%
Shares short (prior month 15 Mar 2024) ⁴	579.33k

Dividends & splits

Forward annual dividend rate ⁴	N/A
Forward annual dividend yield ⁴	N/A
Trailing annual dividend rate ³	0.00
Trailing annual dividend yield ³	0.00%
5-year average dividend yield ⁴	N/A
Payout ratio ⁴	0.00%
Dividend date ³	N/A
Ex-dividend date ⁴	N/A
Last split factor ²	2:1
Last split date ³	08 Mar 2002

Financial highlights

Fiscal year

Fiscal year ends	31 Dec 2023
Most-recent quarter (mrq)	31 Dec 2023

Profitability

Profit margin	-23.86%
Operating margin (ttm)	14.24%

Management effectiveness

Return on assets (ttm)	1.77%
Return on equity (ttm)	-6.94%

Income statement

Revenue (ttm)	2.67B
Revenue per share (ttm)	91.45
Quarterly revenue growth (yoy)	-6.70%
Gross profit (ttm)	N/A
EBITDA	511.6M
Net income avi to common (ttm)	-637.32M
Diluted EPS (ttm)	-21.83
Quarterly earnings growth (yoy)	-57.80%

Balance sheet

Total cash (mrq)	1.61B
Total cash per share (mrq)	56.35
Total debt (mrq)	1.41B
Total debt/equity (mrq)	16.08%
Current ratio (mrq)	5.83
Book value per share (mrq)	306.51

Cash flow statement

Operating cash flow (ttm)	374.9M
Levered free cash flow (ttm)	170.82M